Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

被引：440

作者：

Adamska, Aleksandra ^{[1
]}

Domenichini, Alice ^{[1
]}

Falasca, Marco ^{[1
]}

机构：

[1] Curtin Univ, Metab Signalling Grp, Sch Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2017年 / 18卷 / 07期

关键词：

PDAC; chemotherapy; gemcitabine; Abraxane; FOLFIRINOX; combination therapies; targeted therapies; PHASE-II TRIAL; COOPERATIVE-ONCOLOGY-GROUP; GEMCITABINE-BASED CHEMORADIATION; PACLITAXEL PLUS GEMCITABINE; MTOR INHIBITOR EVEROLIMUS; PLACEBO-CONTROLLED TRIAL; GROWTH-FACTOR RECEPTOR; NEOADJUVANT THERAPY; DOUBLE-BLIND; PREOPERATIVE CHEMORADIATION;

D O I：

10.3390/ijms18071338

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed.

引用

页数：43

共 287 条

[71] Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation [J].

Fountzilas, George ;

Bobos, Mattheos ;

Kalogera-Fountzila, Anna ;

Xiros, Nikolaos ;

Murray, Samuel ;

Linardou, Helena ;

Karayannopoulou, Georgia ;

Koutras, Angelos K. ;

Bafaloukos, Dimitrios ;

Samantas, Epaminondas ;

Christodoulou, Christos ;

Economopoulos, Theofanis ;

Kalogeras, Konstantine T. ;

Kosmidis, Paris .

CANCER INVESTIGATION, 2008, 26 (08) :784-793

[72] nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer [J].

Frese, Kristopher K. ;

Neesse, Albrecht ;

Cook, Natalie ;

Bapiro, Tashinga E. ;

Lolkema, Martijn P. ;

Jodrell, Duncan I. ;

Tuveson, David A. .

CANCER DISCOVERY, 2012, 2 (03) :260-269

[73] A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial [J].

Fuchs, C. S. ;

Azevedo, S. ;

Okusaka, T. ;

Van Laethem, J. -L. ;

Lipton, L. R. ;

Riess, H. ;

Szczylik, C. ;

Moore, M. J. ;

Peeters, M. ;

Bodoky, G. ;

Ikeda, M. ;

Melichar, B. ;

Nemecek, R. ;

Ohkawa, S. ;

Swieboda-Sadlej, A. ;

Tjulandin, S. A. ;

Van Cutsem, E. ;

Loberg, R. ;

Haddad, V. ;

Gansert, J. L. ;

Bach, B. A. ;

Carrato, A. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :921-927

[74]

Fundation R., PHASE 2R PHASE 3 TRI

[75] A novel integrin α5β1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells [J].

Gao, R. ;

Brigstock, D. R. .

GUT, 2006, 55 (06) :856-862

[76] Pancreatic cancer: from state-of-the-art treatments to promising novel therapies [J].

Garrido-Laguna, Ignacio ;

Hidalgo, Manuel .

NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (06) :319-334

[77] Prognostic factors in the operative treatment of ductal pancreatic carcinoma [J].

Gebhardt, C ;

Meyer, W ;

Reichel, M ;

Wünsch, PH .

LANGENBECKS ARCHIVES OF SURGERY, 2000, 385 (01) :14-20

[78] PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy [J].

Gill, Sharlene ;

Ko, Yoo-Joung ;

Cripps, Christine ;

Beaudoin, Annie ;

Dhesy-Thind, Sukhbinder ;

Zulfiqar, Muhammad ;

Zalewski, Pawel ;

Do, Thuan ;

Cano, Pablo ;

Lam, Wendy Yin Han ;

Dowden, Scot ;

Grassin, Helene ;

Stewart, John ;

Moore, Malcolm .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3914-+

[79] Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages [J].

Gillen, Sonja ;

Schuster, Tibor ;

zum Bueschenfelde, Christian Meyer ;

Friess, Helmut ;

Kleeff, Joerg .

PLOS MEDICINE, 2010, 7 (04)

[80] MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity [J].

Giovannetti, Elisa ;

Funel, Niccola ;

Peters, Godefridus J. ;

Del Chiaro, Marco ;

Erozenci, Leyla A. ;

Vasile, Enrico ;

Leon, Leticia G. ;

Pollina, Luca E. ;

Groen, Annemieke ;

Falcone, Alfredo ;

Danesi, Romano ;

Campani, Daniela ;

Verheul, Henk M. ;

Boggi, Ugo .

CANCER RESEARCH, 2010, 70 (11) :4528-4538

← 3 4 5 6 7 8 9 10 11 12 →